PPAR-y2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China
Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. M...
Saved in:
Published in | 中国药理学报:英文版 no. 2; pp. 255 - 261 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-~2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-y2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (0R=0.515, 95% Cl 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (0R=1.984, 95% Cl 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-y2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-y2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. |
---|---|
Bibliography: | pioglitazone; type 2 diabetes; PPAR-y2 rs1801282; PTPRD rs17584499; genetic polymorphisms; Chinese Han population Aim: To investigate the influence of peroxisome proliferator-activated receptor y2 (PPAR-y2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-~2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-y2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (0R=0.515, 95% Cl 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (0R=1.984, 95% Cl 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-y2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-y2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy. 31-1347/R |
ISSN: | 1671-4083 1745-7254 |